Vacuna Cansino (China)
Fase 1
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395: 1845–54. https://doi.org/10.1016/S0140-6736(20)31208-3
Fase 2
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Publicado online July 20, 2020. https://doi.org/10.1016/S0140-6736(20)31605-6
Vacuna ARN Moderna
Fase 1
An mRNA Vaccine against SARS-CoV-2 —Preliminary Report. N Engl J Med 2020 Nov 12; 383(20):1920-1931. https://doi.org/10.1056/NEJMoa2022483
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med 2020 Dec 3. https://doi.org/10.1056/NEJMc2032195
Fase 1 en adultos mayores
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 2020;383:2427-38. https://doi.org/10.1056/NEJMoa2028436
Vacuna Oxford
Fases 1/2
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet Publicado online July 20, 2020. https://doi.org/10.1016/S0140-6736(20)31604-4
Fases 2/3 (también incluyen personas mayores)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet Publicado online Nov 19, 2020. https://doi.org/10.1016/S0140-6736(20)32466-1
Análisis interino de fases 2/3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Publicado online Dec 8, 2020. https://doi.org/10.1016/S0140-6736(20)32661-1
Vacuna inactivada (virus entero) desarrollada en Wuhan – China
Fases 1/2
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes. Interim Analysis of 2 Randomized Clinical Trials. JAMA, publicado online August 23, 2020. https://doi.org/10.1001/jama.2020.15543
Vacuna Gamaleya
Fases 1/2
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet Publicado online September 4, 2020. https://doi.org/10.1016/S0140-6736(20)31866-3
Vacuna ARN Pfizer
Fase 1 (prueban dos)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med published online October 14, 2020. https://doi.org/10.1056/NEJMoa2027906
Fases 2/3
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med publicado Dec 10, 2020. https://doi.org/10.1056/NEJMoa2034577
Vacuna inactivada National Biotec Group & Beijing Institute of Biological Products (BBIBP-CorV)
Fases 1/2
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2020; publicado online Oct 15. https://doi.org/10.1016/S1473-3099(20)30831-8
Vacuna recombinante de la proteína S (Novavax)
Fases 1/2
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med 2020;383:2320-32. https://doi.org/10.1056/NEJMoa2026920